Investors Tire of A...
Health Care: Drugs
NexMed Inc. (NEXM: NASDAQ)
$2.20 -0.06 | -2.65%
09/24/10 - 03:59 PM ET
47.90K / 157.00K
Vol / Avg. Vol:2.25 / 2.26
Open / Prev. Close:2.20 - 2.29
Today's Range:1.93 - 3.38
52 Wk Range:1084.21%
Performance YTD:TheStreet Rating:
Portfolios with NEXM
- Portfolio NameUser Type
- Userbiotech
- UserGains
- UserAlain's Portfolio
- Usergrandpicks
- UserM0nkD Portfolio 1
- UserSWIFT
- UserLong Shot 2
- UserStoermer
- Usermy TK holdings
- Userjw1
Latest NEXM Headlines from TheStreet
- NexMed, Inc. Q2 2010 Earnings Call Transcript 08.13.10 | 02:08 pm
- NexMed, Inc. Q1 2010 Earnings Call Transcript 05.14.10 | 02:05 pm
- China Direct, Taseko Mines: Early Volume Plays 05.13.10 | 08:05 am
- Wave Systems, NexMed: Early Volume Plays 05.11.10 | 08:05 am
- Dynavax, Frontier Financial: Early Volume Plays 04.27.10 | 07:04 am
- Biotech Stock Mailbag: NexMed 02.12.10 | 07:02 am
- SkyPeople, NexMed: Late Day Volume Plays 01.19.10 | 03:01 pm
- Sunesis, U.S. Energy: Early Volume Plays 12.11.09 | 09:12 am
- Midday Movers: Pump Up the Volume 10.14.09 | 01:10 pm
- Thursday's Small-Cap Winners and Losers 02.01.07 | 01:02 pm
Press Releases for NEXM
- NexMed, Inc. Announces Results Of Special Meeting Of Stockholders, Including Name Change To Apricus Biosciences - Business Wire 09.10.10 | 04:09 pm
- NexMed To Present At The Rodman & Renshaw 12th Annual Healthcare Conference - Business Wire 08.25.10 | 11:08 am
- NexMed Receives Additional Patent Coverage For Israel - Business Wire 08.23.10 | 09:08 am
- NexMed Announces 2010 Second Quarter Financial Results Conference Call - Business Wire 08.11.10 | 09:08 am
- Mohamed Hachicha, Ph.D. Joins NexMed, Inc. As Vice President-Research And Development For NexMed, USA - Business Wire 07.26.10 | 12:07 pm
- NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation Is Bioequvalent To Talconex® - Business Wire 06.15.10 | 09:06 am
- NexMed Provides Update On Canadian Filing For Vitaros® - Business Wire 06.10.10 | 01:06 pm
- NexMed Announces Expansion Of Senior Business Development Team - Business Wire 05.25.10 | 05:05 pm
- NexMed To Discuss P2/3 Protocol For NexACT®-Based Alprostadil Treatment For Raynaud’s Syndrome With The FDA - Business Wire 05.17.10 | 05:05 pm
- NexMed Announces Pre-Clinical Study Showing Vitaros® Significantly Promotes Wound Healing - Business Wire 05.12.10 | 04:05 pm
Partner Headlines for NEXM
- UPDATE 1-NexMed says FDA may allow cancer drug into late stage - Reuters 04.26.10 | 06:04 pm
